4.6 Article

Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jtcvs.2009.02.003

关键词

-

资金

  1. Homer Flower Gene Therapy Research Fund
  2. Charles Rogers Gene Therapy Fund
  3. Flora & Stuart Mason Lung Cancer Research Fund
  4. Charles B. Swank Memorial Fund for Esophageal Cancer Research
  5. George O. Sweeney Fund for Esophageal Cancer Research
  6. Phalan Thoracic Gene Therapy Fund
  7. M. W. Elkins Endowed Fund

向作者/读者索取更多资源

Introduction: The impact of esophageal tumor length on pT1 esophageal adenocarcinoma has not been well evaluated. Methods: Case histories of all patients (n = 133) undergoing esophageal resection from 1979 to 2007 with pT1 adenocarcinoma of the esophagus were reviewed. Univariate and multivariate analyses of esophageal tumor length and other standard prognostic factors were performed. Results: Patients with early-stage pT1 esophageal adenocarcinoma with tumors less than 3 cm demonstrate decreased long-term survival (3 years:>3 cm = 46% vs 93%; P<.001) and higher risk of lymph node involvement (lymph node positive:>3 cm - 47% vs 10%; P<.001). Multivariable analysis shows that esophageal tumor length (>3 cm) is an independent risk factor for survival in patients with pT1 early-stage esophageal cancer (hazard ratio: 4.8, 95% confidence intervals: 1.4-16.5; P<.001) even when controlled for submucosal involvement, lymph node involvement, and lymphatic/ vascular invasion status. In combination with submucosal involvement, esophageal tumor length (>3 cm) identifies a high-risk population of pT1 esophageal adenocarcinoma (3 years: group 1 [0 risk factors] = 100%, group 2 [1 risk factor] = 87%, and group 3 [2 risk factors] = 33%; P<.001). Conclusions: This study demonstrates that esophageal tumor length (>3 cm) is a risk factor for long-term survival and lymph node involvement in early-stage pT1 esophageal adenocarcinoma. Esophageal tumor length (>3 cm) in combination with submucosal involvement may help to identify a high-risk group of patients with pT1 esophageal adenocarcinoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据